{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Angiotensin-Converting Enzyme",
      "SARS-CoV-2",
      "angiotensin",
      "renin-angiotensin-aldosterone system"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33925881",
  "DateCompleted": {
    "Year": "2021",
    "Month": "05",
    "Day": "11"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "05",
    "Day": "18"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "04",
        "Day": "26"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "4503",
      "10.3390/ijms22094503"
    ],
    "Journal": {
      "ISSN": "1422-0067",
      "JournalIssue": {
        "Volume": "22",
        "Issue": "9",
        "PubDate": {
          "Year": "2021",
          "Month": "Apr",
          "Day": "26"
        }
      },
      "Title": "International journal of molecular sciences",
      "ISOAbbreviation": "Int J Mol Sci"
    },
    "ArticleTitle": "Dysregulation of the Renin-Angiotensin-Aldosterone System (RAA) in Patients Infected with SARS-CoV-2-Possible Clinical Consequences.",
    "Abstract": {
      "AbstractText": [
        "SARS-CoV-2 impairs the renin-angiotensin-aledosterone system via binding ACE2 enzyme. ACE2 plays a key role in the biosynthesis of angiotensin (1-7), catalyzing the conversion of angiotensin 2 into angiotensin (1-7) and the reaction of angiotensin synthesis (1-9), from which angiotensin is (1-7) produced under the influence of ACE (Angiotensin-Converting Enzyme). Angiotensin 2 is a potent vasoconstrictor and atherogenic molecule converted by ACE2 to reducing inflammation and vasodilating in action angiotensin (1-7). Angiotensin (1-9), that is a product of angiotensin 1 metabolism and precursor of angiotensin (1-7), also exerts cell protective properties. Balance between angiotensin 2 and angiotensin (1-7) regulates blood pressure and ACE2 plays a critical role in this balance. ACE2, unlike ACE, is not inhibited by ACE inhibitors at the doses used in humans during the treatment of arterial hypertension. Membrane ACE2 is one of the receptors that allows SARS-CoV-2 to enter the host cells. ACE2 after SARS-CoV-2 binding is internalized and degraded. Hence ACE2 activity on the cell surface is reduced leading to increase the concentration of angiotensin 2 and decrease the concentration of angiotensin (1-7). Disturbed angiotensins metabolism, changes in ratio between angiotensins with distinct biological activities leading to domination of atherogenic angiotensin 2 can increase the damage to the lungs."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Biochemistry, Faculty of Medicine, Medical University of Gda\u0144sk, 80-211 Gda\u0144sk, Poland."
          }
        ],
        "LastName": "Dettlaff-Pokora",
        "ForeName": "Agnieszka",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "State School of Higher Vocational Education, 75-582 Koszalin, Poland."
          }
        ],
        "LastName": "Swierczynski",
        "ForeName": "Julian",
        "Initials": "J"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Switzerland",
    "MedlineTA": "Int J Mol Sci",
    "NlmUniqueID": "101092791",
    "ISSNLinking": "1422-0067"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Angiotensins"
    },
    {
      "RegistryNumber": "EC 3.4.15.1",
      "NameOfSubstance": "ACE protein, human"
    },
    {
      "RegistryNumber": "EC 3.4.15.1",
      "NameOfSubstance": "Peptidyl-Dipeptidase A"
    },
    {
      "RegistryNumber": "EC 3.4.17.23",
      "NameOfSubstance": "ACE2 protein, human"
    },
    {
      "RegistryNumber": "EC 3.4.17.23",
      "NameOfSubstance": "Angiotensin-Converting Enzyme 2"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Angiotensin-Converting Enzyme 2"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Angiotensins"
    },
    {
      "QualifierName": [
        "pathology",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Peptidyl-Dipeptidase A"
    },
    {
      "QualifierName": [
        "physiology"
      ],
      "DescriptorName": "Renin-Angiotensin System"
    },
    {
      "QualifierName": [
        "isolation & purification",
        "metabolism"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Virus Internalization"
    }
  ],
  "CoiStatement": "The authors declare no conflict of interest."
}